Tissue viral load variability in chronic hepatitis C

American Journal of Gastroenterology

Volumn 96, Issue 12, 2001, Pages 3384-3389

  Fanning, Liam ^a   Loane, Joseph ^a   Kenny Walsh, Elizabeth ^a   Sheehan, Margaret ^a   Whelton, Michael ^a   Kirwan, William ^a   Collins, John Kevin ^a   Shanahan, Fergus ^a  

^a University College Cork and INFANT Centre   (Ireland)

Author keywords

[No Author keywords available]

Indexed keywords

VIRUS RNA;

ADULT; AGED; ARTICLE; CHRONIC HEPATITIS; CLINICAL ARTICLE; FEMALE; GENOTYPE; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; HUMAN TISSUE; INFLAMMATION; LIVER BIOPSY; LIVER CIRRHOSIS; LIVER FIBROSIS; MALE; PRIORITY JOURNAL; RISK FACTOR; VIRUS LOAD;

ADULT; AGED; BLOOD; FEMALE; FIBROSIS; HEPACIVIRUS; HEPATITIS C, CHRONIC; HUMANS; LIVER; MALE; MIDDLE AGED; VIRAL LOAD;

EID: 0035666696     PISSN: 00029270     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-9270(01)03833-3     Document Type: Article

References (31)

1. In vivo tropism of hepatitis C virus genomic sequences in hematopoietic cells: Influence of viral load, viral genotype, and cell phenotype
2. Clinical outcomes after hepatitis C infection from contaminated anti-D immune globulin
3. Interaction of alcohol and hepatitis C virus infection on severity of liver disease
4. The natural course of chronic hepatitis C: Implications for clinical practice
5. Role of alcohol in the progression of liver disease caused by hepatitis C virus infection
6. Natural history of liver fibrosis progression in patients with chronic hepatitis C
7. Significance of serum hepatitis C virus RNA levels in chronic hepatitis C
8. Anti-hepatitis C antibodies, and non-A, non-B post-transfusion hepatitis in the Netherlands
9. The MHC is a major determinant of viral status, but not fibrotic stage, in individuals infected with hepatitis C
10. Viral load and clinicopathological features of chronic hepatitis C (1b) in a homogeneous patient population
11. Assessment of hepatitis C virus quasispecies heterogeneity by gel shift analysis: Correlation with response to interferon therapy
12. Hepatitis C viral quasispecies in hepatitis C virus carriers with normal liver enzymes, and patients with type C chronic liver disease
13. Serum hepatitis C virus RNA quantity, and histological features of hepatitis C virus carriers with persistently normal ALT levels
14. Intraobserver and interobserver variations in liver biopsy interpretation in patients with chronic hepatitis C
15. Histological grading and staging of chronic hepatitis
16. Phylogenetic analysis of hepatitis C virus isolates and their correlation to viremia, liver function tests, and histology
17. Relationship of aminotransferases to liver histological status in chronic hepatitis C
18. Genotypes and titers of hepatitis C virus for predicting response to interferon in patients with chronic hepatitis C
19. Hepatitis C virus RNA quantification in right and left lobes of the liver in patients with chronic hepatitis C
20. Sampling error associated with a needle liver biopsy in patients with chronic hepatitis C virus infection
21. Randomised trial of interferon alpha2b plus ribavirin for 48 weeks or for 24 weeks versus interferon alpha2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus
22. Randomised, double-blind, placebo-controlled trial of interferon alpha-2b with, and without ribavirin for chronic hepatitis C
23. Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C
24. Histopathological concordance of paired renal allograft biopsy cores. Effect on the diagnosis and management of acute rejection
25. Classification of chronic hepatitis: Diagnosis, grading and staging
26. Terminology of chronic hepatitis, hepatic allograft rejection and nodular lesions of the liver: Summary of recommendations developed by an International Working Party, supported by the World Congresses of Gastroenterology, Los Angeles
27. HCV RNA level, and histopathology is similar in needle biopsy from different part of the liver
28. Clinical outcome of chronic hepatitis C in patients treated with interferon: Comparison between responders and non-responders
29. Use of interferon for prevention of hepatocellular carcinoma in cirrhotic patients with hepatitis B or hepatitis C virus infection
30. Is antiviral treatment (IFN alpha and/or ribavirin) justified in cirrhosis related to hepatitis C virus?
31. Hepatitis C virus resistance to antiviral therapy